Synlogic Investor Relations Material

Synlogic, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases. Synlogic’s product candidates include SL-401, which is a drug candidate for the treatment of Type 1 Diabetes Mellitus, a rare metabolic disease; SL-701, which is an orally administered synthetic biotic therapeutic designed to regulate the gut microbiome to protect against Clostridium difficile infection; and SL-701 as a treatment for Multiple Sclerosis.